Logos Capital is a San Francisco-based investment firm dedicated to advancing healthcare through disciplined, data-driven investments in biotechnology. Founded in 2019 by Dr. Arsani William, a former Farallon Capital Management alumnus, the firm combines scientific and financial expertise to identify transformative therapies in healthcare.

Their approach integrates in-house data analytics with clinical trial modeling to assess the intrinsic value of each opportunity, aiming to generate superior long-term returns for investors. Logos Capital's mission is to drive groundbreaking progress in healthcare by providing the financial foundation for innovations that elevate the standard of care and improve patient lives. The firm's philosophy emphasizes a holistic approach to drug development, considering both scientific and operational aspects, and involves thorough event tracking, clinical trial underwriting, and proactive management.

Their proprietary data science platform, Logos Analytics, enhances decision-making by predicting clinical trial outcomes with exceptional precision, enabling well-informed investment decisions that drive value creation.